| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
13,866 |
11,668 |
$465K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,408 |
5,969 |
$279K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
767 |
726 |
$71K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
668 |
642 |
$58K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,006 |
1,874 |
$52K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
660 |
639 |
$39K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
3,071 |
1,444 |
$33K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,847 |
1,744 |
$25K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
611 |
529 |
$19K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
225 |
218 |
$18K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
65 |
55 |
$16K |
| 99000 |
|
1,488 |
1,367 |
$16K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
325 |
292 |
$15K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
132 |
127 |
$11K |
| 80053 |
Comprehensive metabolic panel |
2,153 |
1,829 |
$8K |
| 80061 |
Lipid panel |
1,659 |
1,426 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,159 |
1,861 |
$6K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
582 |
497 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
601 |
475 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
310 |
274 |
$5K |
| 87428 |
|
119 |
112 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
604 |
585 |
$3K |
| 97169 |
|
222 |
204 |
$3K |
| 93000 |
|
468 |
403 |
$3K |
| 87807 |
|
256 |
240 |
$3K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
34 |
30 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,108 |
959 |
$3K |
| 99337 |
|
44 |
36 |
$3K |
| 92551 |
|
590 |
561 |
$2K |
| 90461 |
|
366 |
267 |
$2K |
| 84703 |
|
347 |
320 |
$2K |
| 81003 |
|
1,476 |
1,314 |
$2K |
| 0071A |
|
41 |
40 |
$2K |
| 99215 |
Prolong outpt/office vis |
40 |
30 |
$2K |
| 90674 |
|
258 |
231 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
66 |
65 |
$985.27 |
| 0072A |
|
22 |
22 |
$894.00 |
| 99310 |
Prolong nursin fac eval 15m |
26 |
26 |
$746.94 |
| 71046 |
Radiologic examination, chest; 2 views |
58 |
42 |
$738.49 |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
17 |
16 |
$559.63 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
74 |
62 |
$307.46 |
| 90734 |
|
220 |
204 |
$246.51 |
| 99309 |
Subsequent nursing facility care, per day, low to moderate complexity |
76 |
52 |
$241.26 |
| 0011A |
|
27 |
25 |
$240.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
17 |
17 |
$165.66 |
| 0013A |
|
15 |
15 |
$160.00 |
| 99072 |
|
822 |
682 |
$150.00 |
| 99350 |
Prolong home eval add 15m |
15 |
15 |
$138.17 |
| 0031A |
|
38 |
38 |
$135.87 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
59 |
50 |
$131.70 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
144 |
120 |
$85.05 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
129 |
115 |
$54.16 |
| 90651 |
|
89 |
84 |
$50.01 |
| A4208 |
Syringe with needle, sterile 3 cc, each |
418 |
334 |
$42.25 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
53 |
34 |
$15.39 |
| 96127 |
|
147 |
132 |
$8.88 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
66 |
65 |
$8.30 |
| 94760 |
|
66 |
65 |
$4.22 |
| 36415 |
Collection of venous blood by venipuncture |
3,136 |
2,771 |
$3.60 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
58 |
57 |
$2.18 |
| 91307 |
|
67 |
63 |
$0.05 |
| 90662 |
|
12 |
12 |
$0.03 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
64 |
55 |
$0.03 |
| 91303 |
|
37 |
37 |
$0.02 |
| G9744 |
Patient not eligible due to active diagnosis of hypertension |
1,141 |
890 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
454 |
371 |
$0.00 |
| 99173 |
|
2,096 |
1,975 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
395 |
320 |
$0.00 |
| 1159F |
|
5,124 |
3,617 |
$0.00 |
| 90670 |
|
15 |
13 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
9,827 |
6,930 |
$0.00 |
| Q2037 |
Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (fluvirin) |
79 |
77 |
$0.00 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,519 |
1,134 |
$0.00 |
| 90633 |
|
31 |
30 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
153 |
120 |
$0.00 |
| 90715 |
|
92 |
88 |
$0.00 |
| 90707 |
|
15 |
14 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
30 |
28 |
$0.00 |
| 91300 |
|
15 |
15 |
$0.00 |
| G8783 |
Normal blood pressure reading documented, follow-up not required |
60 |
46 |
$0.00 |
| 90710 |
|
27 |
25 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
534 |
406 |
$0.00 |
| 3008F |
|
4,149 |
3,043 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
990 |
778 |
$0.00 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
2,998 |
2,117 |
$0.00 |
| G8419 |
Bmi documented outside normal parameters, no follow-up plan documented, no reason given |
123 |
102 |
$0.00 |
| 2010F |
|
5,165 |
3,713 |
$0.00 |
| 1036F |
|
4,671 |
3,305 |
$0.00 |
| A9150 |
Non-prescription drugs |
18 |
16 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
322 |
214 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
169 |
82 |
$0.00 |
| 90650 |
|
12 |
12 |
$0.00 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
23 |
23 |
$0.00 |
| 91301 |
|
72 |
60 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
33 |
32 |
$0.00 |
| 90696 |
|
30 |
30 |
$0.00 |
| G8755 |
Most recent diastolic blood pressure >= 90 mmhg |
36 |
29 |
$0.00 |
| G0506 |
Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) |
14 |
14 |
$0.00 |